This company listing is no longer active
CDAK.Q Stock Overview
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Codiak BioSciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.0016 |
52 Week High | US$3.09 |
52 Week Low | US$0.0016 |
Beta | 3.43 |
1 Month Change | -82.22% |
3 Month Change | -92.00% |
1 Year Change | -99.95% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Brokers Are Upgrading Their Views On Codiak BioSciences, Inc. (NASDAQ:CDAK) With These New Forecasts
Nov 08Codiak BioSciences drops 31% postmarket on proposed stock offering
Sep 12Codiak cuts 37% of staff amid plans to reprioritize studies
Aug 30Codiak begins dosing in early-stage trial for liver, gastric, colorectal cancers
Jun 29Broker Revenue Forecasts For Codiak BioSciences, Inc. (NASDAQ:CDAK) Are Surging Higher
Mar 15Codiak BioSciences, Inc. (NASDAQ:CDAK) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 09Codiak BioSciences announces key promotions
Jun 15Codiak names Jennifer Wheler as chief medical officer
May 10Insider Buying: The Codiak BioSciences, Inc. (NASDAQ:CDAK) Independent Director Just Bought US$100k Worth Of Shares
Feb 18What Percentage Of Codiak BioSciences, Inc. (NASDAQ:CDAK) Shares Do Insiders Own?
Jan 14Codiak posts positive initial phase 1 results for exoil-12
Dec 30Codiak BioSciences EPS beats by $13.68, beats on revenue
Nov 19Shareholder Returns
CDAK.Q | US Biotechs | US Market | |
---|---|---|---|
7D | -77.1% | -0.4% | -0.6% |
1Y | -99.9% | 5.5% | 22.2% |
Return vs Industry: CDAK.Q underperformed the US Biotechs industry which returned 2.5% over the past year.
Return vs Market: CDAK.Q underperformed the US Market which returned 12.6% over the past year.
Price Volatility
CDAK.Q volatility | |
---|---|
CDAK.Q Average Weekly Movement | 61.5% |
Biotechs Industry Average Movement | 10.7% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CDAK.Q's share price has been volatile over the past 3 months.
Volatility Over Time: CDAK.Q's weekly volatility has increased from 36% to 62% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 102 | n/a | www.codiakbio.com |
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines.
Codiak BioSciences, Inc. Fundamentals Summary
CDAK.Q fundamental statistics | |
---|---|
Market cap | US$58.93k |
Earnings (TTM) | -US$17.42m |
Revenue (TTM) | US$34.07m |
0.0x
P/S Ratio0.0x
P/E RatioIs CDAK.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CDAK.Q income statement (TTM) | |
---|---|
Revenue | US$34.07m |
Cost of Revenue | US$54.81m |
Gross Profit | -US$20.74m |
Other Expenses | -US$3.32m |
Earnings | -US$17.42m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -0.47 |
Gross Margin | -60.89% |
Net Profit Margin | -51.13% |
Debt/Equity Ratio | 66.0% |
How did CDAK.Q perform over the long term?
See historical performance and comparison